Merck Kidney Cancer Drug Succeeds in Two Large Trials

Merck kidney cancer drug succeeds in two large trials

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its top-selling immunotherapy Keytruda loses patent protection.

Merck (NYSE: MRK): DFS benefit with KEYTRUDA + WELIREG vs KEYTRUDA alone in RCC

Phase 3 LITESPARK-022 topline: KEYTRUDA + WELIREG improved DFS vs KEYTRUDA alone in adjuvant clear cell RCC after nephrectomy; OS follow-up ongoing.

Non–Clear Cell RCC Trials Support Regimens Approved for Clear Cell RCC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

During a live event, Randy F. Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma.